OTC : CMVLF

Cellectis S.A.

$3.47 USD

$0.39 (12.66%)

Volume
1.4K
Average Volume
3
Market Capitalization
$251.93M
P/E Ratio
-4.37
Dividend Yield
0.00%
Price Target
Year High
$5.04
Year Low
$1.25
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.52
Company Overview

OTC

Andre Choulika

Biotechnology

Healthcare

CMVLF

216

FR

USD

https://www.cellectis.com

33 1 81 69 16 00

N/A

0001627281

Liquidity Metrics

1.38

1.52

1.52

0.26

0.00

Sales & Valuation

$75.92M

3.13

4.95

-5.34

-0.40

Profitability

-$0.7

-$70.34M

-98.69%

-101.81%

-80.61%

-23.26%

P/E Metrics

-4.37

0.05

0.05

Analyst Price Target & Rating

N/A

0/5

10 Analysts

%

Financial Health Scores

-1.26

2/9

$70.25M

$289.98M

$229.9M

-$64.66M

Key Metrics (TTM)

$260.64M

3.83

-5.80

1.52

-80.61%

-27.24%

-22.66%

-18.73%

-352 days

Company Executives
Name Title
Jean Charles Epinat Chief Technological Officer
Marie-Bleuenn Terrier General Counsel & Secretary of the Board of Directors
Stephan Reynier Chief Regulatory & Pharmaceutical Compliance Officer
Kyung Nam-Wortman Executive Vice President & Chief Human Resources Officer
Andre Choulika Co-Founder, Chief Executive Officer & Director
David J. Sourdive Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and Director
Philippe Duchateau Chief Scientific Officer
Arthur Stril Chief Financial Officer & Chief Business Officer
Valerie Cros Principal Financial Officer & Principal Accounting Officer
Pascalyne Wilson Director of Communications
Poll Results

No votes yet today — be the first to share your view!

About Cellectis S.A. (OTC:CMVLF) Stock

Cellectis S.A. is a clinical-stage biotechnology firm dedicated to advancing immuno-oncology therapies. Their core technology involves engineering T-cells with gene editing to express chimeric antigen receptors (CARs), enabling these modified cells to precisely target and destroy cancer cells. The company's operations are structured into two principal divisions: Therapeutics and Plants. Its robust development pipeline includes several crucial product candidates. Notable among these is UCART19, an allogeneic T-cell treatment designed for CD19-expressing blood cancers like acute lymphoblastic leukemia. They are also progressing ALLO-501 and ALLO-501A, aimed at tackling relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. Further candidates encompass ALLO-316 for renal c ... ell carcinoma, UCART123 for acute myeloid leukemia, and UCART22 for B-cell acute lymphoblastic leukemia. Additionally, the company is advancing UCARTCS1 and ALLO-715 in its efforts against multiple myeloma. Cellectis has forged significant strategic partnerships with organizations such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. Furthermore, it maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was established in 1999 and its headquarters are located in Paris, France.

Frequently Asked Questions

What is the current Cellectis S.A. (CMVLF) stock price?

Cellectis S.A.(OTC:CMVLF) stock price is $3.47 in the last trading session. During the trading session, CMVLF stock reached the peak price of $5.04 while $1.25 was the lowest point it dropped to. The percentage change in CMVLF stock occurred in the recent session was 12.66% while the dollar amount for the price change in CMVLF stock was $0.39.

CMVLF's industry and sector of operation?

The OTC listed CMVLF is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CMVLF?

Jean Charles Epinat | Chief Technological Officer
Marie-Bleuenn Terrier | General Counsel & Secretary of the Board of Directors
Stephan Reynier | Chief Regulatory & Pharmaceutical Compliance Officer
Kyung Nam-Wortman | Executive Vice President & Chief Human Resources Officer
Andre Choulika | Co-Founder, Chief Executive Officer & Director

How many employees does CMVLF have?

Number of CMVLF employees currently stands at 216. CMVLF operates from 8, rue de la Croix Jarry, Paris, None 75013, FR.

Link for CMVLF official website?

Official Website of CMVLF is: https://www.cellectis.com

How do I contact CMVLF?

CMVLF could be contacted at phone #33 1 81 69 16 00 and can also be accessed through its website. CMVLF operates from 8, rue de la Croix Jarry, Paris, None 75013, FR.

How many shares of CMVLF are traded daily?

The average number of CMVLF shares traded daily for last 3 months was 3.

What is the market cap of CMVLF currently?

The market value of CMVLF currently stands at $251.93M with its latest stock price at $3.47